A novel ex vivo high-throughput assay reveals antiproliferative effects of idelalisib and ibrutinib in chronic lymphocytic leukemia

PI3Kδ (idelalisib) and BTK (ibrutinib) inhibitors have demonstrated significant clinical activity in chronic lymphocytic leukemia (CLL) interfering with the cross-talk between CLL cells and the lymph node microenviroment, yet their mechanism of action remains to be fully elucidated. Here, we develop...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Oncotarget
Main Authors: Primo, Daniel, Scarfò, Lydia, Xochelli, Aliki, Mattsson, Mattias, Ranghetti, Pamela, Espinosa, Ana Belén, Robles, Alicia, Gorrochategui, Julian, Martínez-López, Joaquín, de la Serna, Javier, González, Marcos, Gil, Alberto Chaparro, Anguita, Eduardo, Iraheta, Sandra, Munugalavadla, Veerendra, Quéva, Christophe, Tannheimer, Stacey, Rosenquist, Richard, Stamatopoulos, Kostas, Ballesteros, Joan, Ghia, Paolo
Formato: Artigo
Idioma:Inglês
Publicado em: Impact Journals LLC 2018
Assuntos:
Research Paper
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5995261/
https://ncbi.nlm.nih.gov/pubmed/29899839
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.25419
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados